Rockefeller Capital Management
DNTH icon

Rockefeller Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Rockefeller Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-188
Closed -$4K – 3917
2022
Q3 		$4K Sell
188
-37
-16% -$1.01K ﹤0.01% 3388
2022
Q2 		$4K Hold
225
– – ﹤0.01% 3523
2022
Q1 		$10K Hold
225
– – ﹤0.01% 3029
2021
Q4 		$15K Hold
225
– – ﹤0.01% 2776
2021
Q3 		$26K Buy
+225
New +$26.2K ﹤0.01% 2467

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Rockefeller Capital Management's DNTH Position: Q4 2022 in Review

Rockefeller Capital Management sold out of Dianthus Therapeutics (DNTH) in Q4 2022, closing a stake of 188 shares — an estimated $4K sold.

Rockefeller Capital Management first reported a position in DNTH in Q3 2021 and held it in 5 quarters. The position peaked at $26K in Q3 2021. 53 funds tracked by Wall St. Rank hold DNTH as of Q4 2022.

  • Rockefeller Capital Management reported no remaining Dianthus Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Rockefeller Capital Management sold 188 Dianthus Therapeutics shares in Q4 2022, an estimated $4K.
  • Rockefeller Capital Management first reported a position in Dianthus Therapeutics in Q3 2021 and held it in 5 quarters.
  • Rockefeller Capital Management's Dianthus Therapeutics position peaked at $26K in Q3 2021.
  • 53 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2022.

Based on Rockefeller Capital Management's 13F filing for Q4 2022, filed 6 Mar 2023.